US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection

This article describes FDA’s rationale for labeling determinations in situations where limited data made these decisions challenging.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research